Cellectar BioSciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 20
- Market Cap
- -
- Website
- http://www.cellectar.com
- Introduction
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.
Clinical Trials
16
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05610891
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
- Conditions
- DIPGNeuroblastomaEwing SarcomaPediatric Solid TumorPediatric Brain TumorRhabdomyosarcomaOsteosarcomaPediatric Lymphoma
- Interventions
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03478462
- Locations
- 🇺🇸
Lucile Packard Children's Hospital, Palo Alto, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Duke University, Chapel Hill, North Carolina, United States
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
- Conditions
- Small Lymphocytic LymphomaLymphoplasmacytic LymphomaWaldenstrom MacroglobulinemiaMultiple MyelomaMarginal Zone LymphomaDiffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell LymphomaCentral Nervous System Lymphoma
- Interventions
- Drug: Iopofosine I 131 single doseDrug: Iopofosine I 131 multiple doseDrug: Iopofosine I 131 fractionated dose
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT02952508
- Locations
- 🇬🇧
Cellectar Biosciences site, London, United Kingdom
🇹🇷Cellectar Biosciences, Istanbul, Turkey
🇮🇱Cellectar Biosciences Site, Jerusalem, Israel
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02278315
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01898273
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸University of Maryland School of Medicine, Baltimore, Maryland, United States
- Prev
- 1
- 2
- 3
- Next
News
Cellectar Biosciences Submits Phase 1b Protocol for CLR 125 Radiopharmaceutical in Triple-Negative Breast Cancer
Cellectar Biosciences has submitted a Phase 1b dose-finding study protocol to the FDA for CLR 125, an iodine-125 Auger-emitting radiopharmaceutical targeting relapsed triple-negative breast cancer.
Cellectar's Iopofosine I 131 Doubles Survival in Pediatric Brain Cancer Trial
Cellectar Biosciences reported that iopofosine I 131 achieved 5.4 months average progression-free survival in pediatric high-grade glioma patients, doubling the reported median of 2.25 months.
Cellectar Biosciences Raises $2.5 Million Through Warrant Exercise to Advance Cancer Drug Development
Cellectar Biosciences secured $2.5 million in funding through the exercise of existing warrants at a reduced price of $0.3041 per share, with proceeds designated for general corporate purposes and operating expenses.
Cellectar Biosciences Advances Iopofosine I 131 and Radioconjugate Pipeline at Biotech Showcase
Cellectar Biosciences plans to highlight its 2025 strategic initiatives at the Biotech Showcase during the JP Morgan Healthcare Conference.
Cellectar Biosciences to Pursue Strategic Options for Iopofosine I 131, Prioritizes Solid Tumor Radiotherapies
Cellectar Biosciences is exploring strategic alternatives for iopofosine I 131 after recent FDA feedback on regulatory pathways.
Cellectar Biosciences' Iopofosine I 131 Shows Promise in Waldenstrom's Macroglobulinemia
Cellectar Biosciences reported positive Phase 2 CLOVER-WaM study results for Iopofosine I 131 in relapsed/refractory Waldenstrom's Macroglobulinemia (WM).
Cellectar Biosciences Advances Iopofosine I 131 in Multiple Myeloma and Waldenstrom’s Macroglobulinemia Trials
Cellectar Biosciences is progressing its lead therapeutic, iopofosine I 131, through clinical trials targeting relapsed/refractory Waldenstrom’s macroglobulinemia (WM) and multiple myeloma (MM).